ViGenCell, Inc.

ViGenCell, Inc.

KKRX:308080
4,395.00
KRW
+120.00
(+2.81%)
-647.62EPS
128.12BMarket Cap

Total Valuation

KRW

As of June 30, 2026, ViGenCell, Inc. carries a market capitalization of 128.12B, placing it among publicly traded companies globally. Its enterprise value stands at 105.98B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap128.12B
Enterprise Value105.98B

Share Statistics

As of June 30, 2026, ViGenCell, Inc. has 20.50M shares outstanding.

Shares Outstanding20.50M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 138.96, and the price-to-book ratio stands at 3.30.

PS Ratio138.96
PB Ratio3.30
P/TBV Ratio3.38
P/FCF Ratio-11.11
P/OCF Ratio-11.82

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 114.94 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 105.98B versus a market cap of 128.12B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales114.94

Financial Position

As of June 30, 2026, ViGenCell, Inc. maintains a current ratio of 15.27, meaning it holds 15.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.10, indicating elevated leverage, while an interest coverage ratio of -45.43 demonstrates limited ability to service its debt obligations.

Current Ratio15.27
Quick Ratio14.64
Debt / Equity19.10
Debt / EBITDA-0.65
Interest Coverage-45.43

Financial Efficiency

KRW

Over the twelve months ended June 30, 2026, ViGenCell, Inc. posted a negative return on equity (ROE) of -29.38, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -24.02, reflecting losses generated across the asset base. The company generates approximately 19.21M in revenue per employee across its workforce of 48.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-29.38
Return on Assets (ROA)-24.02
Revenue Per Employee19.21M
Employee Count48.00

Stock Price Statistics

KRW

As of the close on November 17, 2026, ViGenCell, Inc.'s stock has gained approximately 35.23% over the past 52 weeks. The 50-day moving average sits at 5,447.00, while the 200-day moving average is 6,768.05.

52-Week Price Change35.23%
50-Day Moving Average5,447.00
200-Day Moving Average6,768.05

Income Statement

KRW

Over the twelve months ended June 30, 2026, ViGenCell, Inc. generated 921.98M in revenue and converted that into -13.28B in net income, yielding earnings per share of -647.62. EBITDA reached -11.31B, while operating income came in at -14.14B.

Revenue921.98M
Gross Profit44.70M
Operating Income-14.14B
Pretax Income-13.28B
Net Income-13.28B
EBITDA-11.31B
EBIT-14.14B
Earnings Per Share (EPS)-647.62

Balance Sheet

KRW

As of June 30, 2026, ViGenCell, Inc. holds 29.55B in cash and equivalents against 7.41B in total debt, resulting in a net debt position of -8.16B. Total book value stands at 38.79B, with working capital of 28.81B providing operational flexibility.

Cash & Cash Equivalents29.55B
Total Debt7.41B
Net Debt-8.16B
Equity (Book Value)38.79B
Book Value Per Share1,892.30
Working Capital28.81B

Cash Flow

KRW

ViGenCell, Inc. produced -10.84B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -694.95M in capital expenditures, free cash flow totaled -11.54B - equivalent to -562.77 per share.

Operating Cash Flow-10.84B
Capital Expenditures-694.95M
Free Cash Flow-11.54B
FCF Per Share-562.77

Margins

Over the twelve months ended June 30, 2026, ViGenCell, Inc. posted a gross margin of 4.85, reflecting its pricing power and cost economics. The operating margin of -1,533.39 and net profit margin of -1,439.86 provide insight into operational efficiency.

Gross Margin4.85
Operating Margin-1,533.39
Pretax Margin-1,439.86
Profit Margin-1,439.86
EBITDA Margin-1,226.95

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -9.00: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.05, meaning ViGenCell, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-0.05
FCF Yield-9.00

Stock Splits

ViGenCell, Inc.'s most recent stock split took place on June 8, 2022 with a 1:2 split ratio.

Last Split Date6/8/2022
Split Ratio1:2

Scores

As of June 30, 2026, ViGenCell, Inc. has an Altman Z-Score of 3.30, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.30